Premium
Ribozyme‐targeting reveals the rate‐limiting role of pleiotrophin in glioblastoma
Author(s) -
Grzelinski Marius,
Bader Nicole,
Czubayko Frank,
Aigner Achim
Publication year - 2005
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.21276
Subject(s) - pleiotrophin , cancer research , cell growth , biology , downregulation and upregulation , midkine , in vivo , angiogenesis , growth factor , receptor , gene , biochemistry , genetics , microbiology and biotechnology
Glioblastomas (GBMs) are the most frequent malignant brain tumors with very limited treatment options and nearly all GBM patients dying within 1 year. Pleiotrophin (PTN, HB‐GAM, HBNF, OSF‐1) is a secreted growth factor that shows mitogenic, chemotactic and transforming activity. While PTN expression is tightly regulated during embryogenesis and very limited in normal adult tissues, a marked PTN upregulation is seen in tumors including glioblastomas. Targeting of the PTN receptors, ALK and RPTP‐zeta, indicates a contribution of PTN‐activated signaling pathways in glioblastomas. However, the relevance of PTN expression itself is unknown especially since, besides PTN, at least one more growth factor, midkine (MK), signals through ALK and is expressed in glioblastoma. Here we demonstrate the biologic relevance of PTN in 2 glioblastoma cell lines in vitro and in vivo . We show that stable ribozyme‐targeting leads to a robust reduction of PTN mRNA and protein levels. This results in decreased cell proliferation, cell migration and soft agar colony formation in vitro . Comparing clonal ribozyme‐transfected cells with different residual PTN levels, we establish a PTN gene‐dose effect of glioblastoma cell proliferation. In a subcutaneous tumor xenograft mouse model, in vivo growth is markedly reduced upon PTN depletion, which is paralleled by decreased PTN serum levels. Furthermore, the immunohistochemical analysis of the tumors shows reduced angiogenesis in PTN‐depleted tumors. We conclude that PTN is a rate‐limiting growth factor in glioblastoma. Since PTN is overexpressed in glioblastomas but rarely found in normal tissue, PTN may represent an attractive therapeutic target. © 2005 Wiley‐Liss, Inc.